MIMRYLO
Live / Applied — Second extension granted (statement of use) (as of 02 Mar 2026)
What this means for you
Not registered yet, but its 04 Oct 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98786114
- Mark type
- Stylized text
- Filed
- 04 Oct 2024
- Published for opposition
- 01 Apr 2025
- Attorney of record
- Karl M. Zielaznicki, Esq.
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals for use in the treatment of cancer and blood diseases and disorders
Owner
- Takeda Pharmaceuticals U.S.A., Inc., Cambridge, MA, US
- Takeda Pharmaceuticals U.S.A., Inc., Cambridge, MA, US
Prosecution history
- 03 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Mar 2026 — SOU EXTENSION 2 GRANTED
- 02 Mar 2026 — SOU EXTENSION 2 FILED
- 02 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 08 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 30 Sept 2025 — SOU EXTENSION 1 GRANTED
- 30 Sept 2025 — SOU EXTENSION 1 FILED
- 30 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 27 May 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 01 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 01 Apr 2025 — PUBLISHED FOR OPPOSITION
- 26 Mar 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 10 Mar 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 31 Jan 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 30 Jan 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE